AI assistant
Sending…
ATOSSA THERAPEUTICS, INC. — Director's Dealing 2025
Oct 21, 2025
34113_dirs_2025-10-21_19c8efd5-f70a-4e1f-829f-4d8fa4f04e0c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ATOSSA THERAPEUTICS, INC. (ATOS)
CIK: 0001488039
Period of Report: 2025-10-14
Reporting Person: Daniel Mark James (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-10-14 | Stock Option (right to buy) | $1.03 | A | 578000 | Acquired | 2035-10-14 | Common Stock (578000) | Direct |
Footnotes
F1: The options shall vest with respect to 25% on October 14, 2026, with the remaining 75% to vest in equal quarterly installments over the follwing three years, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
More from ATOSSA THERAPEUTICS, INC.
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 8
Declaration of Voting Results & Voting Rights Announcements
2026
May 8
Regulatory Filings
2026
Apr 16
Director's Dealing
2026
Mar 31
Annual Report
2026
Mar 25
Proxy Solicitation & Information Statement
2026
Mar 20
Capital/Financing Update
2026
Feb 20
Delisting Announcement
2026
Feb 17
Regulatory Filings
2026
Feb 11